FOS and colorectal carcinoma: We selected TROP2, also known as TACSTD2, for further analysis because (i) its overexpression in CRC has been linked to poor prognosis and high metastatic burden [19], and (ii) our in silico analysis identified several ATF2- and AP1-binding sites in the TROP2 promoter (Supplementary Table 4).